| Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC |
2019-08-06 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| Twist Bioscience–Imagene: nucleic acid storage technology, 201907– supply service DNA encapsulation using DNAshell technology |
2019-07-25 |
| Infarco–Keensight Capital: investment, 201907 acquisition of Infarco’s majority stake in 3P Biopharmaceuticals by Keensight |
2019-07-23 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer |
2019-07-17 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties |
2019-07-12 |
| Microphyt–CEA Industrie: investment, 201907 financing round totalling €28.5m incl existing + co-investor Supernova Invest |
2019-07-11 |
| Microphyt–Demeter: investment, 201907 financing round totalling €28.5m incl existing + co-investor Demeter Partners |
2019-07-11 |
| Microphyt–France (govt): investment, 201907 financing round totalling €28.5m incl new + co-lead investor Bpifrance SPI Fund |
2019-07-11 |
| Microphyt–Irdi Soridec: investment, 201907 financing round totalling €28.5m incl existing + co-investor Irdi Soridec |
2019-07-11 |
| Microphyt–iXO Private Equity: investment, 201907 financing round totalling €28.5m incl new + co-investor iXO Private Equity |
2019-07-11 |
| Microphyt–Safilaro: investment, 201907 financing round totalling €28.5m incl new + co-investor Sofilaro |
2019-07-11 |
| Microphyt–SEVERAL: investment, 201907 financing round €28.5m co-led by Sofinnova Partners + Bpifrance SPI Fund |
2019-07-11 |
| Microphyt–Sofinnova: investment, 201907 financing round totalling €28.5m incl new + co-lead investor Sofinnova Partners |
2019-07-11 |
| Nosopharm–Evotec: antibiotics, 201907– collab €na pre-clinical developm of NOSO-502 + 2nd generation odilorhabdin |
2019-07-03 |
| Oncovita–Andrew Lloyd Associates: public relations, 201907 service existent by ALA |
2019-07-02 |
| Oncovita–Institut Pasteur: cancer immunotherapy, 201907– license excl ww €na for use of oncolytic measles virus platform for product developm + sale |
2019-07-02 |
| Oncovita–Institut Pasteur: investment, 201907 existent Institut Pasteur is shareholder of Oncovita |
2019-07-02 |
| Sanifit–Andera Partners: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Andera Partners |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds |
2019-06-26 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| SQZ Biotechnologies–Erytech: drug delivery technology, 201906– license to red blood cell encapsulation from Erytech to develop immunomodulators |
2019-06-24 |
| Terns Pharmaceuticals–Genfit: elafibranor, 201906– license excl $35m upfront + $193m milestones + royalties for Greater China |
2019-06-24 |
| Sanofi–Alphabet: healthcare informatics, 201906– collab new virtual innovation lab using Google Cloud for future medicines + healthcare services |
2019-06-18 |
| Ipsen–Debiopharm: triptorelin, 201906– strategic collab extension 15y developm + prod + distrib Decapeptyl in Europe + certain Asia + Africa |
2019-06-12 |
| Medidata Solutions–Dassault Systèmes: investment, 201906– acquisition $5.8b cash tender offer at $92.25/share ANNOUNCED |
2019-06-12 |
| Servier–Yposkesi: lentiviral vectors, 201906– collab developm + GMP manufacture of lentiviral vectors for CAR-T cell technology development |
2019-06-05 |
| Yukin Therapeutics–Advent France Biotechnology: investment, 201906 financing round totalling €3.3m incl founding + co-lead investor Advent France Bio |
2019-06-04 |
| Yukin Therapeutics–Medicxi Ventures: investment, 201906 financing round totalling €3.3m incl new + co-lead investor Medicxi |
2019-06-04 |
| Yukin Therapeutics–NewCap: public relations, 201906 service existent by NewCap |
2019-06-04 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| Domain Therapeutics–BPCE: investment, 201905 investment €3.5m from existing investor Seventure Partners |
2019-05-28 |
| Sensorion–Institut Pasteur: gene therapy, 201905– collab framework agreem incl license options for gene therapies for ear diseases |
2019-05-27 |
| DNA Script–France (govt): investment, 201905 financing round Series B totalling $38.5m incl new investor Bpifrance Large Venture fund |
2019-05-16 |
| DNA Script–Idinvest Partners: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Idinvest Partners |
2019-05-16 |
| DNA Script–Illumina: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Illumina Ventures |
2019-05-16 |
| DNA Script–Kurma: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Kurma Partners |
2019-05-16 |
| DNA Script–Life Sciences Partners: investment, 201905 financing round Series B totalling $38.5m incl new + lead investor LSP |
2019-05-16 |
| DNA Script–Merck (DE): investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor M Ventures |
2019-05-16 |
| DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP |
2019-05-16 |
| DNA Script–Sofinnova: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Sofinnova Partners |
2019-05-16 |
| TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA |
2019-05-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al |
2019-05-13 |
| Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
| Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
| Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
| Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
| AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO |
2019-05-02 |
| Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson |
2019-05-02 |
| Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures |
2019-04-30 |
| Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners |
2019-04-30 |
| Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance |
2019-04-30 |
| Alentis Therapeutics–High-Tech Gründerfonds: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor HTGF |
2019-04-30 |
| Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif |
2019-04-30 |
| Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq |
2019-04-30 |
| Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures |
2019-04-30 |
| JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen |
2019-04-29 |
| Cisbio Bioassays–PerkinElmer: investment, 201904 acquisition by PerkinElmer |
2019-04-25 |
| Genecast (CN)–HalioDx: cancer test, 201904– distribution excl of Immunoscore Colon Assay in China by Genecast |
2019-04-19 |
| Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group |
2019-04-09 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France |
2019-04-03 |
| AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF |
2019-04-03 |
| AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes |
2019-04-03 |
| AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax |
2019-04-03 |
| AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology |
2019-04-03 |
| AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures |
2019-04-03 |
| Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments |
2019-04-01 |
| Cellnovo–NONE: investment, 201903 in administration |
2019-03-28 |
| Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA |
2019-03-28 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners |
2019-03-28 |
| H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 |
2019-03-27 |
| Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF |
2019-03-21 |
| Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) |
2019-03-20 |
| Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares |
2019-03-20 |
| Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects |
2019-03-14 |
| BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m |
2019-03-05 |
| Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB |
2019-03-05 |
| Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TreeFrog Therapeutics–SEVERAL: grant, 201903 non-dilutive funding €600k from Nouvelle-Aquitaine Region + Bpifrance + French Ministry of Research |
2019-03-01 |
| Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market |
2019-02-27 |
| Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures |
2019-02-21 |
| BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund |
2019-02-20 |
| BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al |
2019-02-20 |
| BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan |
2019-02-20 |
| Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate |
2019-02-14 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px](/banner/iito-20190626-650-112-life-sciences-usa-transatlantic-beta-version.jpg)
![Picture [iito] – Putting Information into Context 600x60px](/banner/iito-20181119-600-060-iito-business-intelligence-putting-information-into-context.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
